Most investors want to enjoy what they earn from the markets. To do so, their money needs to generate above market returns with low market risk. That’s Rule No. 1. One of the best ways to do just that is by studying billionaires like Warren Buffett, Baron Rothschild and Sir John Templeton, and applying their…
DetailsApparently, the buck stops with Donald Trump. Since the 1990’s, administrations have fought to keep a strong dollar policy to keep interest rates low, to keep inflation under control and to keep our buying power stronger. But that’s quickly changing. After an incredible 13% run from May 2016 lows, the U.S. dollar is under pressure,…
DetailsJust three weeks into the New Year, the yellow metal may be up 3%, but aluminum is up 8%. Copper is up 17%. All as excitement builds for Donald Trump’s multi-billion dollar infrastructure plans. But what you may not be aware of is that the run in aluminum and copper is far from over. We’re…
DetailsSometimes, size does matter. For quite some time, small cap stocks languished thanks to a number of factors, including a crash in commodities. Then, for most of 2016, traders ignored them. But since the election, small caps have become one of the biggest sector winners on the market. That’s likely to continue well into 2017…
DetailsBy far, it was the most powerful – most lucrative move we’ve ever seen. Between January 2012 and July 2015, the NASDAQ Biotech Index (NBI) rallied from a low of 1,144.05 to a high of 4,194.87. All on the heels of mergers and acquisitions, retiring baby boomers, millions of newly insured Americans, heavy demand and…
Details2016 began well for gold traders. In the first six months, gold bugs watched the metal soar from $1,070 to a high of $1,376.50. Then, with a stronger dollar, rate hikes, and the election, the metal turned south shortly after. The other headwind has been India, which could limit gold exports and reduce overall global…
DetailsUnemployment may have ticked higher to 4.7% in December, but it still remains just shy of the lowest level since August 2007. Better yet, since President Obama took office, the number of employed Americans reportedly jumped by 9.9 million. But while it may sound like great news, remember this. Over the last eight years, 14.6…
DetailsOne of the single best biotech stocks to own went unnoticed for months. But it would go on to produce potential gains of 4,800%. In 2010, we recommended that very stock, ACADIA Pharmaceuticals (ACAD) at $1.24. It would eventually rocket to a high of $51.99 before pulling back. However, smart investors are again waking up…
DetailsSometimes, the smaller, the better. A common misconception about smaller cap companies is that their volatility makes them more risky, and therefore, they are not worth the gamble. But the reality is that many of them generate returns that are as good as, if not better than, large cap stocks. In fact, in 2016 alone,…
DetailsSmall cap stocks were some of the best performers of 2016. In fact, since January 2016, the Russell 2000 gained 23% on the year, as the Dow picked up 17%. The NASDAQ was up 11% on the year. The S&P 500 up 13%. Fund managers expect the small cap rally to extend well into the…
DetailsIt’s a fool’s trade. Or rather, we should say, it was. After infuriating investors with bankruptcy filings and crumbling valuations for years, stem cell companies have been crushed. Many suffered delays, burning through cash with few results. StemCells – now Microbot Medical (MBOT) — fell from a $228 high in 2014 to less than $4…
DetailsIt may be one of the most controversial topics. But it’s not going away. In fact, the marijuana story is just heating up – again. In fact, we’ve already seen several of the biggest stocks soar in 2016 alone after several more states voted to legalize its recreational and medicinal use. GW Pharmaceuticals (GWPH) soared…
Details